US COVID-19 Relief Law Boosts Pharmaceutical Manufacturing Programs; Is More To Come?
$10bn here and $6bn there on top of what’s left from earlier CARES Act gives government more options on COVID-19 medical countermeasures.
You may also be interested in...
BARDA and Development Financing Corp. officials provide insights into window of opportunity for partnering on manufacturing scale-up.
President Biden’s 100-day plan relies on Defense Production Act authorities to increase resilience of critical domestic pharmaceutical supplies.
BARDA’s suspension of funding for COVID-19 therapeutics risks repeating mistakes of past pandemics as it may cause industry to pull out of the development space, experts say. Industry sources are concerned the Biden administration is focusing on funding NIH at the expense of BARDA.